The Claim
Propranolol treatment in hyperthyroid patients is associated with a small but measurable reduction in serum triiodothyronine (T3) from 4.6 to 3.9 nmol/L over one month, while atenolol does not produce this change.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with hyperthyroidism, propranolol lowers serum triiodothyronine (T3) levels from 4.6 to 3.9 nmol/L after one month of treatment, whereas atenolol does not lower T3 levels under the same conditions.
See the scientific wording
Propranolol treatment in hyperthyroid patients is associated with a small but measurable reduction in serum triiodothyronine (T3) from 4.6 to 3.9 nmol/L over one month, while atenolol does not produce this change.
Propranolol blocks a specific enzyme in the body that converts one thyroid hormone into another, causing less of the active hormone T3 to be made. Atenolol does not block this enzyme, so T3 levels stay the same.
What the research says
1 studyStudy: Non-selective and selective beta-1-adrenoceptor blocking agents in the treatment of hyperthyroidism.
In people with an overactive thyroid, one medicine called propranolol slightly lowers a specific thyroid hormone (T3) after a month, but another medicine called atenolol doesn't do that — and this study proves it.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.